Imiquimod for the treatment of oral leukoplakia: A two‐center retrospective study

作者：Hervé Sroussi, Alessandro Villa, Malak Al‐Hadlaq, Kentaro Ikeda, Sivappiriyai Veluppillai, Nathaniel S. Treister, Anette Vistoso Monreal, Piamkamon Vacharotayangul, Michele Lodolo, Sook‐Bin Woo · 发表于：Oral Diseases · 年份：2024 · DOI：10.1111/odi.15069 · 被引用次数：10 · 研究领域：Oral Health Pathology and Treatment、Oral and Maxillofacial Pathology、Oral and gingival health research

OBJECTIVES: We aimed to assess the effectiveness of the use of topical imiquimod for the management of oral leukoplakia (OL). METHODS: This was a retrospective study. Medical chart reviews were conducted to identify patients with biopsy-proven OL treated with topical 5% imiquimod. Data included OL characteristics, histopathological diagnosis, treatment outcome, and adverse events (AEs). Treatment response was assessed by measuring the percentage reduction in the size of OL lesions. RESULTS: 33 patients (51.5% females; median age: 65 years) with 38 lesions were included. OLs were either localized (23.7%) or multifocal lesions (76.3%), with the majority on the gingiva (86.8%). Pretreatment histopathological diagnoses were dysplasia in 84.2% and nonreactive hyperkeratosis in 15.8%. Most regimens consisted of 60-minute applications, 5-days-a-week, for 6 weeks. At the end of treatment, 81.6% of 38 lesions showed a reduction in size with 68.4% exhibiting ≥50% reduction in size, and 42.1% exhibiting complete resolution. Application site reactions were the most common with pain/soreness/sensitivity occurring in 86.8%. Fatigue was the most frequently reported systemic AE (28.9%). CONCLUSION: Two-thirds of OL lesions had ≥50% reduction in size. Most AEs were temporary and resolved upon treatment discontinuation. Prospective studies are needed to further assess Imiquimod's effectiveness in OL management.